Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.48 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.45 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.45 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.42 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250 | 0.97 | — | — | |
| Bromide SCHEMBL20984751 | 0.94 | IDO1 (0.48) | IDO1LMNACYP1A2CYP3A4CYP2D6 | |
| Water SCHEMBL9206581 | 0.94 | IDO1 (0.48) | IDO1LMNACYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4372170 | 0.86 | SOS1 (0.47) | IDO1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL14675465 | 0.86 | MEN1 (0.47) | IDO1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27864424 | 0.85 | IDO1 (0.47) | IDO1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27559226 | 0.85 | ACHE (0.62) | IDO1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4371426 | 0.83 | SOS1 (0.48) | IDO1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14683165 | 0.83 | MEN1 (0.49) | IDO1LMNACYP1A2CYP3A4CYP2D6 | |
| Phosphoric Acid SCHEMBL20985041 | 0.83 | CA12 (0.53) | IDO1LMNACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317742-A1 | METHODS OF PREPARING INTERMEDIATES OF HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED | 2024-09-26 | — | — | US | claimed |
| CN-114276305-B | Trisubstituted phenyl-1, 2, 4-triazole derivative, preparation method thereof and application thereof in treatment of neuronal injury | 中山大学 | 2023-11-17 | — | — | CN | claimed |
| CN-116478134-A | SSRI/5-HT 1A Double-target antidepressant formylpiperidine compound and preparation method and application thereof | 上海医药工业研究院有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-115160227-A | Heterozygote of R-or S-2- (1-acetoxy-n-pentyl) benzoic acid and 4-fluoro-edaravone, and preparation and application thereof | 中国药科大学 | 2022-10-11 | — | — | CN | claimed |
| CN-114591254-A | 3, 5-disubstituted phenyl-1, 2, 4-triazole derivative and preparation method and application thereof | 中山大学 | 2022-06-07 | — | — | CN | claimed |
| CN-114478410-A | Disubstituted phenyl-1, 2, 4-triazole derivative and preparation and application thereof | 中山大学 | 2022-05-13 | — | — | CN | claimed |
| CN-114276305-A | Tri-substituted phenyl-1, 2, 4-triazole derivative, preparation thereof and application thereof in treating neuronal injury | 中山大学 | 2022-04-05 | — | — | CN | claimed |
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2021-06-22 | — | — | US | claimed |
| CN-107892685-B | Piperine derivative, preparation method and application thereof in preparation of botanical insecticide | 西北农林科技大学 | 2021-01-01 | — | — | CN | claimed |
| CN-107540627-B | Dehydroabietic acid oxadiazine heterocyclic derivatives with antibacterial activity and preparation method and application thereof | 南京林业大学 | 2020-11-03 | — | — | CN | claimed |
| CN-107663161-B | Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt | 上海惠和化德生物科技有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2019-05-23 | — | — | US | claimed |
| CN-106749288-B | N- (substituted-phenyl) Bi Zuo Bing fraxinellones analog derivative, preparation method and application | 郑州大学 | 2018-07-10 | — | — | CN | claimed |
| CN-107892685-A | Pipering analog derivative, preparation method and its application for preparing plant insecticide | 西北农林科技大学 | 2018-04-10 | — | — | CN | claimed |
| CN-107286549-A | Antibacterial resin and preparation method thereof | 立得光电科技股份有限公司 | 2017-10-24 | — | — | CN | claimed |
| CN-106749288-A | N (substituted benzene) base Bi Zuo Ji fraxinellones analog derivative, its preparation method and application | 郑州大学 | 2017-05-31 | — | — | CN | claimed |
| CN-106518711-A | Preparation method of 4-fluorophenylhydrazine hydrochloride | 天津市化学试剂研究所有限公司 | 2017-03-22 | — | — | CN | claimed |
| EP-0918052-B1 | Improved polymeric mdi color | BAYER AG (US) | 2003-05-28 | — | — | EP | claimed |
| US-5942151-A | PREVENTING THE DISCOLORATION OF PRODUCING POLYMETHYLENEPOLYPHENYLENE POLYISOCYANATE BY ADDING AN ADDITIVE HYDRAZINE OR A HYDRAZINE DERIVATIVE | BAYER CORPORATION (US) | 1999-08-24 | — | — | US | claimed |
| EP-0918052-A1 | Improved polymeric mdi color | Bayer Corporation (US) | 1999-05-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317742-A1 | METHODS OF PREPARING INTERMEDIATES OF HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A1 | PTGS2 959/4885MAOA 3350/4885MAOB 3621/4885 |
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | HPD, TYR, PDK2 | PTGS2 2185/4885MAOA 136/4885MAOB 220/4885 |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | HPD, TYR, PDK2 | PTGS2 2185/4885MAOA 136/4885MAOB 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.